Stock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and FILSPARI Sales Surge

Stock Track10-31

Travere Therapeutics, Inc. (NASDAQ: TVTX) stock is surging 18.04% in pre-market trading on Friday, building on the impressive 16.29% gain from the previous session. The continued rally comes after the biopharmaceutical company released outstanding third-quarter 2025 financial results, showcasing significant revenue growth and a return to profitability.

For Q3 2025, Travere reported total revenue of $164.9 million, with U.S. net product sales reaching $113.2 million. The standout performer was FILSPARI (sparsentan), the company's key product for IgA Nephropathy (IgAN), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong performance contributed to a net income of $25.7 million, or $0.28 per share, marking a substantial turnaround from the $54.8 million net loss in the same quarter last year.

The market's enthusiasm is further fueled by FILSPARI's growing adoption as a foundational therapy for IgAN, with 731 new patient start forms received during the quarter. Adding to the positive sentiment, TD Cowen raised its price target for Travere Therapeutics from $30 to $40, reflecting increased confidence in the company's growth prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could open up additional revenue streams for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143811640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143811640","market":"hk","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and FILSPARI Sales Surge","media":"Stock Track","content":"<p>Travere Therapeutics, Inc. (NASDAQ: TVTX) stock is surging 18.04% in pre-market trading on Friday, building on the impressive 16.29% gain from the previous session. The continued rally comes after the biopharmaceutical company released outstanding third-quarter 2025 financial results, showcasing significant revenue growth and a return to profitability.</p>\n\n<p>For Q3 2025, Travere reported total revenue of $164.9 million, with U.S. net product sales reaching $113.2 million. The standout performer was FILSPARI (sparsentan), the company's key product for IgA Nephropathy (IgAN), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong performance contributed to a net income of $25.7 million, or $0.28 per share, marking a substantial turnaround from the $54.8 million net loss in the same quarter last year.</p>\n\n<p>The market's enthusiasm is further fueled by FILSPARI's growing adoption as a foundational therapy for IgAN, with 731 new patient start forms received during the quarter. Adding to the positive sentiment, TD Cowen raised its price target for Travere Therapeutics from $30 to $40, reflecting increased confidence in the company's growth prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could open up additional revenue streams for the company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and FILSPARI Sales Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and FILSPARI Sales Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Travere Therapeutics, Inc. (NASDAQ: TVTX) stock is surging 18.04% in pre-market trading on Friday, building on the impressive 16.29% gain from the previous session. The continued rally comes after the biopharmaceutical company released outstanding third-quarter 2025 financial results, showcasing significant revenue growth and a return to profitability.</p>\n\n<p>For Q3 2025, Travere reported total revenue of $164.9 million, with U.S. net product sales reaching $113.2 million. The standout performer was FILSPARI (sparsentan), the company's key product for IgA Nephropathy (IgAN), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong performance contributed to a net income of $25.7 million, or $0.28 per share, marking a substantial turnaround from the $54.8 million net loss in the same quarter last year.</p>\n\n<p>The market's enthusiasm is further fueled by FILSPARI's growing adoption as a foundational therapy for IgAN, with 731 new patient start forms received during the quarter. Adding to the positive sentiment, TD Cowen raised its price target for Travere Therapeutics from $30 to $40, reflecting increased confidence in the company's growth prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could open up additional revenue streams for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1143811640","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143811640","pubTimestamp":1761908302,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Travere Therapeutics, Inc. (NASDAQ: TVTX) stock is surging 18.04% in pre-market trading on Friday, building on the impressive 16.29% gain from the previous session. The continued rally comes after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"股票追踪|Travere Therapeutics盘前飙升18%，得益于出色的第三季度业绩和FILSPARI销售额激增","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Travere Therapeutics, Inc. (NASDAQ: TVTX) stock is surging 18.04% in pre-market trading on Friday, building on the impressive 16.29% gain from the previous session. The continued rally comes after the biopharmaceutical company released outstanding third-quarter 2025 financial results, showcasing significant revenue growth and a return to profitability.\nFor Q3 2025, Travere reported total revenue of $164.9 million, with U.S. net product sales reaching $113.2 million. The standout performer was FILSPARI (sparsentan), the company's key product for IgA Nephropathy (IgAN), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong performance contributed to a net income of $25.7 million, or $0.28 per share, marking a substantial turnaround from the $54.8 million net loss in the same quarter last year.\nThe market's enthusiasm is further fueled by FILSPARI's growing adoption as a foundational therapy for IgAN, with 731 new patient start forms received during the quarter. Adding to the positive sentiment, TD Cowen raised its price target for Travere Therapeutics from $30 to $40, reflecting increased confidence in the company's growth prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could open up additional revenue streams for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143811640","isCrawlerRequest":true}